AstraZeneca to present comprehensive data from its diabetes portfolio and pre-clinical research at EASD 2015

2015年9月11日，星期五

AstraZeneca today announced that 54 abstracts from the company’s research and development in diabetes will be presented at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, 瑞典, 2015年9月14日至18日.

The presentations will include data on a number of approved products for the treatment of type 2 diabetes, 包括Forxiga^® (dapagliflozin) Onglyza^® (saxagliptin) Bydureon^® (每周一次的可注射混悬液艾塞那肽缓释片)和Byetta^® (exenatide)注射, 以及沙格列汀和达格列净联合使用的研究数据, 目前正在接受美国和欧盟监管机构的审查. 另外, several abstracts representing AstraZeneca’s early stage and pre-clinical research explore novel pathways and modalities to address the underlying pathophysiology of diabetes.

伊丽莎白•比约克, 副总统, 心血管和代谢疾病科主任, 全球药物发展, said: “The breadth and depth of research we’re presenting at EASD demonstrates our continuous commitment to developing innovative diabetes treatments. We believe these data reinforce our focus to help healthcare providers and patients with type 2 diabetes reach treatment goals sooner.”

Data assessing patient benefit and effects of combination treatment approaches as well as additional effects in addition to HbA1c reduction:

• 在全国范围内研究患者特征, treatment and prevalence/ incidence of the type 2 diabetes population in 瑞典 (Poster #360, 9月15日星期二, 12:30-13:30 CET(中央东部东京))
• Evaluation of HbA1c and weight reductions in T2D patients initiating dapagliflozin treatment in routine UK primary care (Poster #737, 9月15日星期二, 13:45-14:45 CET(中央东部东京))
• Comparison of the safety of triple therapy with saxagliptin and dapagliflozin add-on to metformin versus sequential add-on (Poster #741, 9月16日星期三, 12:30-13:30 CET(中央东部东京))
• German study evaluating the treatment characteristics and outcomes associated with sulphonylurea vs. 二甲双胍在T2D患者中的应用(口服130号，9月16日星期三，16:00-17:30 CET)
• 达格列净对高血压糖尿病患者蛋白尿的影响(口服185号), 9月17日星期四, 15:30-17:00 CET(中央东部东京))

Real-world and pooled data investigating long-term effects and patient experience to further develop the clinical profile of our medicines:

• Comparison of upper GI adverse events between long-acting GLP-1 receptor agonists and short-acting GLP-1 receptor agonists (Oral #15, 9月15日星期二, 10:45-12:15 CET(中央东部东京))
• Pooled analysis of three trials evaluating the three-year efficacy and safety of once-weekly exenatide (Poster #770, 9月15日星期二, 12:30-13:30 CET(中央东部东京))
• 达格列净对长期HbA1c改善和体重的影响分析(海报#740), 9月16日星期三, 12:30-13:30 CET(中央东部东京))
• Comparison of patient ad在这里nce with exenatide once-weekly versus liraglutide once-daily (Poster #795, 9月16日星期三, 13:45-14:45 CET(中央东部东京))

Investigational new data exploring novel pathways, underlying mechanisms and treatment approaches:

• -3激动剂对总体重和葡萄糖耐量的影响(口服#23), 9月15日星期二, 10:45-12:15 CET(中央东部东京))
• Study examining the effects of combined treatment with saxagliptin and dapagliflozin on beta cell function and insulin levels (Poster #731, 9月15日星期二, 13:45-14:45 CET(中央东部东京))
• Effects of a novel MCH receptor 1 agonist on insulin resistance in pre-clinical modeling (Poster #655, 9月16日星期三, 13:45-14:45 CET(中央东部东京))
• Assessment of dapagliflozin effects on glucagon secretion in murine alpha-cells (Oral # 183, 9月17日星期四, 15:30-17:00 CET(中央东部东京))

完整的澳门葡京网赌游戏数据展示列表可在EASD网站上访问 在这里.

编辑须知

关于2型糖尿病

2型糖尿病是一种以高血糖为特征的慢性疾病, 或高血糖症, 哪一种是身体对胰岛素的无效使用造成的. It comprises 90% of people with diabetes around the world and increases the risk of cardiovascular disease and kidney failure. It is estimated to affect more than 382 million people worldwide and is projected to reach more than 592 million people by 2035. Approximately 77% of people with diabetes live in low- and middle-income countries and 179 million people with diabetes are undiagnosed. It is estimated that more than half of people living with type 2 diabetes are not achieving recommended HbA1c goals based on guidelines established by professional societies and advocacy organisations for diabetes management. 糖尿病的成本和后果在全球范围内都是巨大的, 导致至少6120亿美元的医疗保健支出，并造成4.2014年有900万人死亡——每7秒钟就有一人死亡.

关于澳门葡京网赌游戏糖尿病

AstraZeneca is pushing the boundaries of science to create life-changing medicines that aim to reduce the global burden and complications of diabetes. 重新定义糖尿病患者的预后, 澳门葡京赌博游戏目前的产品组合包括三种最新的非胰岛素类药物, anti-diabetic treatments that support individualised treatment approaches: SGLT-2 inhibitors, GLP-1受体激动剂和DPP-4抑制剂. Our commitment to diabetes is exemplified by the depth and breadth of our global clinical research programme. This commitment is advancing understanding of the treatment effects of our diabetes medicines in broad patient populations, as well as exploring combination treatment approaches resulting in more patients achieving treatment success earlier in their disease progression. 澳门葡京赌博游戏的目标是减少糖尿病的长期影响. 作为公司的核心战略领域, we are focusing our research and development efforts in diverse populations and patients with significant co-morbidities, 比如心血管疾病, 心脏衰竭, 肥胖, 非酒精性脂肪性肝炎(NASH), 慢性肾脏疾病.

关于澳门葡京网赌游戏

澳门葡京网赌游戏是一家全球性的, 专注于发现的创新驱动型澳门葡京赌博游戏企业, 处方药的开发和商业化, 主要用于治疗心血管疾病, 代谢, 呼吸, 炎症, 自身免疫性, 肿瘤学, 感染和神经系统疾病. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 欲知详情，请浏览: www.澳门葡京网赌游戏.com.

联系人